Year: 1998
Type: article
Abstract: The reasons for the emergence and spread of vancomycin-resistant enterococci are not yet fully understood. Nevertheless, various hypotheses and proposals which are being vigorously and extensively debated have been advanced (1-7, 10, 11, 15, 17, 19). The use of avoparcin, another member of the glycopeptide class of antibiotics, as a growth-promoting agent in the production of food animals is often cited as playing a role in the spread of glycopeptide-resistant microorganisms (1, 18, 20). Although it is well recognized that vancomycin resistance is more prevalent in the United States than in Europe, it has not been explained why avoparcin usage fails to correlate with the different epidemiologies of resistance between the two continents; avoparcin was never approved for use in animals in the United States, in contrast to its broad use as a growth-promoting agent in Europe (5, 7, 10).
Authors: Herbert A. Kirst, Diane G. Thompson, Thalia I. Nicas
Institutions: Elanco Animal Health (Germany), Eli Lilly (United States)
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1924960875